Bipolar patients with comorbid anxiety have worse outcomes, and adequate treatment for the anxiety is difficult. One recent study shows ziprasidone no better than placebo. A Canadian task force has offered guidelines.
Polypharmacy in the treatment of bipolar disorder is increasing in Asian countries, despite lack of evidence or support from guidelines. This echoes a broader trend for psychiatric conditions in North America.